MarketInOut Stock Screener Log In | Sign Up
 

Geron Corp

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Geron Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization725.99 mln
Float633 mln
Earnings Date11/04/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-1.91
Caution advised

Relative Strength

26 / 100
Underperforming

Debt / Equity

1.15
Elevated leverage

Pre-Tax Margin

-34%
Deeply loss-making

ROE

-29.57
Deeply negative

Business Description

Geron Corporation is a California-based company that develops medicines to treat blood cancers and related conditions. Its lead approved product, RYTELO, targets an enzyme called telomerase and is used to treat a blood disorder known as myelodysplastic syndromes. The company has several additional treatments in various stages of clinical testing, aimed at conditions including myelofibrosis and acute myeloid leukemia. Founded in 1990, Geron continues to build its portfolio of cancer-focused therapies for patients with limited treatment options.

Key Fundamentals

EPS-0.11
ROE-29.57
RPS0.31
ROIC-24.41
ROA-12.72
Interest Cover-1.24
EBITDA, mln-38.42
EV / EBITDA-20.18
EV / EBIT-19.55
Revenue, mln205
EV / Revenue3.79

Quote Details

Last 1.12
Change -0.01 (-0.88%)
Open 1.15
Volume 11,232,137
Turnover 12,579,993
Average Volume 6,993,303

Financial Ratios

Pre-Tax Profit Margin-34
Leverage Ratio2.37
Current Ratio6.92
Price / Book3.62
Price / Tangible Book3.62
Debt / Equity1.15
Price / Sales4.01

Financial Strength

Altman Z-Score-2.37
Piotroski F-Score 3 / 9
Beneish M-Score-1.91
Short Ratio6.73
Short % of Float11.51

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -4.27% 19 / 100   
1 Month -11.11% 28 / 100   
2 Months -22.22% 21 / 100   
6 Months -25.33% 23 / 100   
1 Year -9.68% 37 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog